Evotec, Janssen collaborate to develop immune-based therapies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Evotec entered into a strategic collaboration and license agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration focuses on the development of first-in-class targeted immune-based therapies for oncology, which will ultimately be commercialized by Janssen. The agreement was facilitated by Johnson & Johnson Innovation.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login